Abstract
Fourteen patients, aged 65–85 years, with refractory (11) or relapsing (3) multiple myeloma were treated with a “protracted-sequential” protocol comprising vincristine 1–2 mg or vindesine 3 mg/M2 (max. 5 mg) IVI over 4 hr on D1, prednisolone 40–50 mg PO D1–14, and melphalan 2–4 mg PO or cyclophosphamide 50–100 mg PO D15–28; cycles were repeated at 4–6 weekly intervals. Treatment was continued for 12 months if the response was optimal or indefinitely if the response was suboptimal. Five patients responded optimally; their survival from the commencement of this protocol ranged from 30 to 120 months. The other nine patients achieved a partial response, their survival ranging from 4+ to 79 months. The treatment is simple, nontoxic, and as convenient as the “classic combination” of melphalan and prednisolone. Am. J. Hematol. 65:81–82, 2000. © 2000 Wiley-Liss, Inc.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
